Feugray Guillaume, Kasonga Fiston, Chamouni Pierre, Barbay Virginie, Fresel Marielle, Hélène Chretien Marie, Brunel Sabine, Le Cam Duchez Véronique, Billoir Paul
Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.
Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.
Clin Biochem. 2022 Feb;100:42-47. doi: 10.1016/j.clinbiochem.2021.11.014. Epub 2021 Nov 26.
Coagulation factor XII (FXII) plays a role in thrombin generation, fibrinolysis, inflammation, angiogenesis, chemotaxis and diapedesis. FXII deficiency is not associated with bleeding risk unlike other coagulation factors.
MATERIALS/METHODS: We investigated thrombin generation assay (TGA) profile modification in FXII deficiency and the correlation with TGA and deficiency severity. TGA was performed in platelet poor plasma (PPP) with tissue factor (1 pmol/L) and phospholipid (4 µmol/L) standardized concentration. Thrombin generation profiles were compared in 54 patients with FXII deficiency, 25 healthy controls and 23 patients with hemophilia A (factor VIII (FVIII) deficiency. Patients with FXII deficiency were classified in three groups based on FXII activity (30-50%, 10-29%, <10%). FVIII deficiency was included as a bleeding control group.
As expected, we found a correlation between FXII deficiency and activated partial thromboplastin time (aPTT). A decrease of thrombin generation was observed in healthy controls and all FXII deficiency groups. A decrease of endogenous thrombin potential (ETP), peak and velocity was observed in patients with FVIII deficiency compared to FXII deficiency. A decrease of thrombin generation was noted in patients with FXII deficiency and bleeding history compared to patients with FXII deficiency and thrombosis history.
In this study, thrombin generation profiles were not sensitive to FXII deficiency. TGA could distinguish bleeding and thrombotic tendency in FXII deficiency. Our results should therefore be considered as exploratory and deserve confirmation.
凝血因子 XII(FXII)在凝血酶生成、纤维蛋白溶解、炎症、血管生成、趋化作用和白细胞渗出中发挥作用。与其他凝血因子不同,FXII 缺乏与出血风险无关。
材料/方法:我们研究了 FXII 缺乏时凝血酶生成试验(TGA)谱的改变及其与 TGA 和缺乏严重程度的相关性。在血小板贫乏血浆(PPP)中,使用组织因子(1 pmol/L)和磷脂(4 μmol/L)标准化浓度进行 TGA。比较了 54 例 FXII 缺乏患者、25 名健康对照者和 23 例甲型血友病(因子 VIII(FVIII)缺乏)患者的凝血酶生成谱。根据 FXII 活性将 FXII 缺乏患者分为三组(30 - 50%、10 - 29%、<10%)。将 FVIII 缺乏作为出血对照组纳入。
正如预期的那样,我们发现 FXII 缺乏与活化部分凝血活酶时间(aPTT)之间存在相关性。在健康对照者和所有 FXII 缺乏组中均观察到凝血酶生成减少。与 FXII 缺乏患者相比,FVIII 缺乏患者的内源性凝血酶潜力(ETP)、峰值和速度降低。与有血栓形成病史的 FXII 缺乏患者相比,有出血病史的 FXII 缺乏患者的凝血酶生成减少。
在本研究中,凝血酶生成谱对 FXII 缺乏不敏感。TGA 可以区分 FXII 缺乏患者的出血和血栓形成倾向。因此,我们的结果应被视为探索性的,值得进一步证实。